natgillin/translations-raw huggingface dataset:
Brinzolamids mulige påvirkning af den corneale endotelfunktion er ikke vurderet hos patienter med kompromitteret cornea (især hos patienter med lavt endotel celletal).
The possible role of brinzolamide on corneal endothelial function has not been investigated in patients with compromised corneas (particularly in patients with low endothelial cell count).
Forsigtighed anbefales også hos patienter med andre former for kompromitteret cornea, som f. eks. diabetikere.
Likewise, in other cases of compromised corneas such as patients with diabetes mellitus, careful monitoring is recommended.
Benzalkoniumklorid, som ofte anvendes som konserveringsmiddel i øjen- præparater, kan ifølge rapporter forårsage punktformet keratopati og/ eller toksisk ulcerøs keratopati.
3 Benzalkonium chloride, which is commonly used as a preservative in ophthalmic products, has been reported to cause punctate keratopathy and/ or toxic ulcerative keratopathy.
Da AZOPT øjendråber indeholder benzalkoniumklorid, er tæt opfølgning nødvendig ved hyppig eller langvarig brug for patienter med tørre øjne eller ved tilfælde, hvor cornea er kompromitteret.
Since AZOPT contains benzalkonium chloride, close monitoring is required with frequent or prolonged use in dry eye patients, or in conditions where the cornea is compromised.
3 AZOPT er ikke afprøvet hos patienter med kontaktlinser.
AZOPT has not been studied in patients wearing contact lenses.
AZOPT indeholder konserveringsmidlet benzalkoniumklorid, som kan give øjenirritation.
AZOPT contains the preservative benzalkonium chloride which may cause eye irritation.
Benzalkoniumklorid kan absorberes af bløde kontaktlinser og er kendt for at kunne misfarve disse.
Benzalkonium chloride may be absorbed by soft contact lenses and is known to discolour soft contact lenses.
Patienter skal derfor instrueres i at vente 15 minutter efter applikation af AZOPT, før kontaktlinserne isættes igen.
Therefore, patients must be instructed to wait 15 minutes after instillation of AZOPT before inserting contact lenses.
AZOPT må ikke appliceres med kontaktlinserne isat.
AZOPT must not be administered while wearing contact lenses.
Potentiel rebound effekt efter seponering af behandling med AZOPT er ikke studeret; den IOP sænkende effekt forventes at holde 5- 7 dage.
Potential rebound effects following cessation of treatment with AZOPT have not been studied; the IOP-lowering effect is expected to last for 5-7 days.
Hos ældre patienter kan perorale karboanhydrase- hæmmere forringe evnen til at udføre opgaver, der kræver mental bevågenhed og/ eller fysisk koordination.
Oral carbonic anhydrase inhibitors may impair the ability to perform tasks requiring mental alertness and/ or physical coordination in elderly patients.
Dette kan også forekomme ved brug af AZOPT, på grund af den systemiske absorption.
AZOPT is absorbed systemically and therefore this may occur with topical administration.
Sammenhæng mellem AZOPT øjendråber og miotika eller adrenerge antagonister er ikke evalueret under samtidig glaukom- terapi.
Association between AZOPT and miotics or adrenergic agonists has not been evaluated during adjunctive glaucoma therapy.
AXOPT er en karboanhydrase- hæmmer som absorberes systemisk trods lokal administration.
AZOPT is a carbonic anhydrase inhibitor and, although administered topically, is absorbed systemically.
De cytokrom p- 450 isozymer, der er ansvarlige for metaboliseringen af brinzolamid, indbefatter CYP3A4 (hovedsagelig), CYP2A6, CYP2C8 og CYP2C9.
The cytochrome P-450 isozymes responsible for metabolism of brinzolamide include CYP3A4 (main), CYP2A6, CYP2C8 and CYP2C9.
Hvis CYP3A4- inhibitorer gives samtidig med brinzolamid, bør man være forsigtig.
Caution is advised if CYP3A4 inhibitors are given concomitantly.
AZOPT bør ikke bruges under graviditet, med mindre det er klart nødvendigt.
AZOPT should not be used during pregnancy unless clearly necessary.
Ammende kvinder Det er uvist, om brinzolamid udskilles i human modermælk, men lægemidlet udskilles i rottemælk.
Nursing mothers It is not known whether brinzolamide is excreted in human milk, however, this substance is excreted in rat milk.
AZOPT øjendråber bør derfor ikke anvendes under amning.
It is strongly recommended to avoid the use of AZOPT when breast-feeding.
4. 7 Virkninger på evnen til at føre motorkøretøjer eller betjene maskiner
4 4.7 Effects on ability to drive and use machines
Forbigående sløret syn og andre synsforstyrrelser kan påvirke evnen til at køre bil og betjene maskiner (se også afsnit 4. 8).
Temporary blurred vision or other visual disturbances, may affect the ability to drive or use machines (see also 4.8 Undesirable effects).
Hvis sløret syn eller andre synsforstyrrelser opstår efter drypning, skal man vente med at køre bil eller betjene maskiner, til synet er klart igen.
If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machinery.
4 4. 8 Bivirkninger
4.8 Undesirable effects
I kliniske undersøgelser med mere end 1800 patienter behandlet med AZOPT som monoterapi eller som tillægsterapi til timolol maleat 5 mg/ ml, var de almindeligste behandlingsrelaterede bivirkninger dysgeusi (5, 8%) (bitter eller unormal smag, se beskrivelsen nedenunder) og forbigående sløret syn (5, 8%) efter applikation, der varede fra få sekunder til få minutter (se også 4. 7 Virkninger på evnen til at føre motorkøretøjer eller betjene maskiner).
In clinical studies involving over 1800 patients treated with AZOPT as monotherapy or adjunctive therapy to timolol maleate 5 mg/ ml, the most frequently reported treatment-related adverse events were: dysgeusia (5.8%) (bitter or unusual taste, see description below) and temporary blurred vision (5.8%) upon instillation, lasting from a few seconds to a few minutes (see also 4.7 Effects on ability to drive and use machines).
Meget almindelig (≥1/ 10), almindelig (> 1/ 100 til, < 1/ 10), ikke almindelig (≥1/ 1. 000 til, < 1/ 100), sjælden (≥1/ 10. 000 til, < 1/ 1000), eller meget sjælden (< 1/ 10, 000).
The following undesirable effects were assessed to be treatment-related and are classified according to the following convention: very common (≥ 1/ 10), common (≥ 1/ 100 to < 1/ 10), uncommon (≥ 1/ 1,000 to < 1/ 100), rare (≥ 1/ 10,000 to < 1/ 1000), or very rare (< 1/ 10,000).
Inden for de forskellige grupper af hyppighed er bivirkningerne opgjort i faldende orden efter alvorlighed.
Within each frequency grouping, undesirable effects are presented in decreasing order of seriousness.
Ikke almindelig: hjerte - og åndedrætsbesvær, angina pectoris, bradykardi, uregelmæssig puls
Uncommon: cardio-respiratory distress, angina pectoris, bradycardia, heart rate irregular
Forstyrrelser i blod - og lymfekarsystemet:
Blood and lymphatic system disorders:
Ikke almindelig: nedsat antal af røde blodlegemer, øget koncentration af klorid i blodet
Uncommon: red blood cell count decreased, blood chloride increased
Almindelig: dysgeusi, hovedpine Ikke almindelig: somnolens, motorisk dysfunktion, amnesi, hukommelsessvækkelse, svimmelhed, paræstesi
Common: dysgeusia, headache Uncommon: somnolence, motor dysfunction, amnesia, memory impairment, dizziness, paraesthesia
Almindelig: blefaritis, sløret syn, øjenirritation, øjensmerte, tørre øjne, pus i øjet, øjenpruritus, følelse af fremmedlegeme i øjet, okulær hyperæmi Ikke almindelig: hornhinde- erosion, keratitis, punktformig keratitis, keratopati, ” søvn ” i øjnene, farvning af hornhinden, defekt i hornhinde- epitelet, øget intraokulært tryk, øget cup til disc ratio, cornea ødem, konjunktivitis, meibomitis, diplopi, blænding, fotofobi, flimren for øjnene, reduceret synsstyrke, allergisk konjunktivitis, pterygium, pigmentering af sclera, astenopi, okulært ubehag, abnorm følelse i øjet, keratokonjunktivitis sicca, hypoæstesi i øjet, subkonjunktival cyste, konjunktival hyperæmi, øjenlågspruritus, skorpedannelse på øjenlåget, øget tåreflåd
Common: blepharitis, blurred vision, eye irritation, eye pain, dry eye, eye discharge, eye pruritus, foreign body sensation in eyes, ocular hyperaemia Uncommon: corneal erosion, keratitis, punctate keratitis, keratopathy, deposit eye, corneal staining, corneal epithelium defect, intraocular pressure increased, optic nerve cup/ disc ratio increased, corneal oedema, conjunctivitis, meibomianitis, diplopia, glare, photophobia, photopsia, visual acuity reduced, allergic conjunctivitis, pterygium, scleral pigmentation, asthenopia, ocular discomfort, abnormal sensation in eye, keratoconjunctivitis sicca, hypoaesthesia eye, subconjunctival cyst, conjunctival hyperaemia, eyelids pruritus, eyelid margin crusting, lacrimation increased
Øre - og labyrintforstyrrelser:
Ear and labyrinth disorders:
Ikke almindelige: tinnitus
Uncommon: tinnitus
Lufveje, thorax og mediastinum:
Respiratory, thoracic and mediastinal disorders:
Ikke almindelig: dyspnø, bronkial hyperaktivitet, hoste, epistaxis, smerter i strube og svælge, halsirritation, nasal kongestion, kongestion af de øvre luftveje, post nasal drip, rhinorrhoea, nysen, nasal tørhed
Uncommon: dyspnoea, bronchial hyperactivity, cough, epistaxis, pharyngolaryngeal pain, throat irritation, nasal congestion, upper respiratory tract congestion, postnasal drip, rhinorrhoea, sneezing, nasal dryness
Almindelig:
Gastrointestinal disorders:
Tør mund Ikke almindelig: oesophagitis, diaré, kvalme, dyspepsi, øvre mavesmerter, mavegener, maveirritation/ ubehag, flatulens, hyppig afføring, gastrointestinale lidelser, oral hypoæstesi, oral paræstesi
Common: dry mouth Uncommon: oesophagitis, diarrhoea, nausea, dyspepsia, upper abdominal pain, abdominal discomfort, stomach discomfort, flatulence, frequent bowel movements, gastrointestinal disorder, hypoaesthesia oral, paraesthesia oral
Lidelser i nyrer og urinveje:
5 Renal and urinary disorders:
Ikke almindelig: nyresmerter
Uncommon: renal pain
Ikke almindelig: urticaria, udslæt, maculopapulært udslæt, generel pruritus, alopeci, stramhed i huden
Uncommon: urticaria, rash, rash maculo-papular, pruritus generalized, alopecia, skin tightness
Muskoloskeletale -, bindevævs - og knoglelidelser:
Musculoskeletal and connective tissue disorders:
Ikke almindelig: rygsmerter, muskelkramper, myalgi
Uncommon: back pain, muscle spasms, myalgia
5 Infektioner og infestationer:
Infections and infestations:
Ikke almindelig: nasopharyngitis, pharyngitis, sinusitis
Uncommon: nasopharyngitis, pharyngitis, sinusitis
Traumer og forgiftning:
Injury, poisoning and procedural complications:
Almene symptomer og reaktioner på administrationsstedet:
General disorders and administrative site conditions:
Ikke almindelig: smerter, ubehag i brystet, asteni, træthed, abnorm følelse, følelse af nervøsitet, irritabilitet
Uncommon: pain, chest discomfort, asthenia, fatigue, feeling abnormal, feeling jittery, irritability
Forstyrrelser i reproduktionssystemet og bryst:
Reproductive system and breast disorders:
Ikke almindelig: apati, depression, depressiv sindsstemning, nedsat libido, mareridt, søvnløshed, nervøsitet
Uncommon: apathy, depression, depressed mood, libido decreased, nightmare, insomnia, nervousness
Bivirkninger, der er påvist i tiden efter markedsføring, og som ikke tidligere er rapporteret i kliniske undersøgelser med AZOPT, er anført nedenfor.
Adverse reactions identified from post-marketing experience that have not been reported previously in clinical trials with AZOPT are listed below.
De stammer fra spontane rapporter ud fra hvilke hyppigheden ikke kan vurderes.
They are derived from spontaneous reports for which the frequency cannot be estimated.
Gruppen af hyppighed er således kategoriseret som ikke kendt.
Thus, the frequency grouping is categorised as not known.
Hjerte: arytmi, hjertebanken, takykardi, hypertension, forhøjet blodtryk, øget hjerterytme
Cardiac disorders: arrhythmia, palpitations, tachycardia, hypertension, blood pressure increased, heart rate increased
Nervesystemet: tremor, hypoæstesi, ageusia
Nervous system disorders: tremor, hypoaesthesia, ageusia
Øjne: sygdom i hornhinde- epitelet, hornhindelidelse, synsforstyrrelse, hævelse af øjet, øjenallergi, madarosis, øjenlågslidelse, øjenlågsødem, øjenlågserytem
Eye disorders: corneal epithelium disorder, corneal disorder, visual disturbance, eye swelling, eye allergy, madarosis, eyelid disorder, eyelid oedema, erythema of eyelid
Øre - og labyrintforstyrrelser: svimmelhed
Ear and labyrinth disorders: vertigo
Lufveje, thorax og mediastinum: astma
Respiratory, thoracic and mediastinal disorders: asthma
Mave- tarmkanalen: opkastning
Gastrointestinal disorders: vomiting
Lidelser i nyrer og urinveje: pollakisuri
Renal and urinary disorders: pollakiuria
Hud og subkutane væv: dermatitis, erytem
Skin and subcutaneous tissue disorders: dermatitis, erythema
Muskoloskeletale -, bindevævs - og knoglelidelser: artralgi, smerter i ekstremiteterne
Musculoskeletal and connective tissue disorders: arthralgia, pain in extremity
Infektioner og infestationer: rhinitis
Infections and infestations: rhinitis
Almene symptomer og reaktioner på administrationsstedet: brystsmerter, perifer ødem, utilpashed, medicinrester
General disorders and administration site conditions: chest pain, peripheral edema, malaise, medication residue
Overfølsomhed
6 Immune system disorders: hypersensitivity
Hepatobilære forstyrrelser: abnorm leverfunktionstest
Hepatobiliary disorders: liver function test abnormal
12, 5% af børnene fik præparatrelaterede bivirkninger, hvoraf størstedelen var lokale, ikke- alvorlige okulære virkninger, så som konjunktival hyperæmi, øjenirritation, pus i øjet og øget tåreflåd (se afsnit 5. 1).
In small short-term clinical trials, approximately 12.5% of paediatric patients were observed to experience drug related adverse effects, the majority of which were local, nonserious ocular effects such as conjunctival hyperaemia, eye irritation, eye discharge, and lacrimation increased (see section 5.1).
6 Dysgeusi (bitter eller unormal smag i munden efter drypning) var den hyppigst forekommende uønskede virkning forbundet med behandling med AZOPT under de kliniske undersøgelser.
Dysgeusia (bitter or unusual taste in the mouth following instillation) was the most frequently reported systemic undesirable effect associated with the use of AZOPT during clinical studies.
Forandringen forårsages sandsynligvis af passage af øjendråberne til naso- pharynx via den nasolacrimale kanal.
It is likely caused by passage of the eye drops in the nasopharynx via the nasolacrimal canal.
Nasolacrimal okklusion eller forsigtig lukning af øjnene efter instillation kan mindske incidensen af denne bivirkning (se også 4. 2 Dosering og indgivelsesmåde).
Nasolacrimal occlusion or gently closing the eyelid after instillation may help reduce the incidence of this effect (see also 4.2 Posology and method of administration).
AZOPT er et sulfonamid, en karboanhydrase- hæmmer, som absorberes systemisk.
AZOPT is a sulphonamide inhibitor of carbonic anhydrase with systemic absorption.
De samme typer uønskede virkninger, der kan skyldes orale karboanhydrase- hæmmere, kan opstå efter topikal administration.
The same type of undesirable effects that are attributable to oral carbonic anhydrase inhibitors may occur with topical administration.
Der er ikke observeret nogen uventede bivirkninger med Azopt, når det anvendes som supplerende terapi til travoprost.
No unexpected adverse events have been observed with AZOPT when used as adjunctive therapy to travoprost.
Bivirkninger, der er påvist ved supplerende terapi, er observeret med hvert af de aktive stoffer brugt alene.
The adverse events seen with the adjunctive therapy have been observed with each active substance alone.
Anti- glaukom præparater og miotika, karboanhydrase- hæmmere, ATC kode:
Antiglaucoma preparations and miotics, carbonic anhydrase inhibitors.
Brinzolamid er en hæmmer af karboanhydrase II (CA- II), det fremherskende isozym i øjet med et in vitro IC50 på 3, 2 nM og et Ki på 0, 13 nM imod CA- II.
Brinzolamide, an inhibitor of carbonic anhydrase II (CA-II), the predominant iso-enzyme in the eye, with an in vitro IC50 of 3.2 nM and a Ki of 0.13 nM against CA-II.
Azopts IOP- sænkende effekt som supplerende terapi til prostaglandinanalogen travoprost er blevet undersøgt.
7 The IOP-reducing effect of AZOPT as adjunctive therapy to the prostaglandin analogue travoprost was studied.
Efter en 4- ugers indkøringsperiode med travoprost, blev patienter med et intraokulært tryk på ≥ 19 mmHg randomiseret til at modtage tillægsbehandling med brinzolamid eller timolol.
Following a 4 week run-in with travoprost, patients with an IOP ≥ 19 mmHg were randomized to receive added treatment with brinzolamide or timolol.
Der blev observeret en yderligere reduktion i det gennemsnitlige diurnale intraokulære tryk på 3, 2 til 3, 4 mmHg for brinzolamid- gruppen og 3, 2 til 4, 2 mmHg for timolol- gruppen.
An additional decrease in mean diurnal IOP of 3.2 to 3.4 mmHg for the brinzolamide group and 3.2 to 4.2 mmHg for the timolol group were observed.
Der var generelt en hyppigere forekomst af ikke- alvorlige okulære bivirkninger, hovedsageligt relateret til tegn på lokal irritation hos brinzolamid/ travoprost- grupperne.
There was an overall higher incidence of non-serious ocular adverse events, mainly related to signs of local irritation, in the brinzolamide/ travoprost groups.
Bivirkningerne var milde og påvirkede ikke den totale andel af patienter, der afbrød behandling (se afsnit 4. 8).
The events were mild and did not affect the overall discontinuation rates in the studies (see section 4.8).
7 Der blev gennemført et klinisk forsøg med AZOPT hos 32 børn på under 6 år med glaukom eller okulær hypertension.
A clinical trial was conducted with AZOPT in 32 paediatric patients less than 6 years of age, diagnosed with glaucoma or ocular hypertension.
Nogle af patienterne havde aldrig fået glaukom medicin før, mens andre allerede blev behandlet med andre typer IOP- sænkende medicin.
Some patients were naive to IOP therapy whilst others were on other IOP-lowering medicinal product(s).
Patienterne blev ikke bedt om at seponere eventuelt IOP- sænkende medicin, før monobehandlingen med AZOPT blev påbegyndt.
Those who had been on previous IOP medicinal products were not required to discontinue their IOP medicinal product(s) until initiation of monotherapy with AZOPT.
Blandt patienterne, som i forvejen ikke fik IOP- sænkende medicin (10 patienter), var virkningen af AZOPT den samme, som er set hos voksne med gennemsnitlige IOP- reduktioner i forhold til baseline på op til 5 mmHg.
Among patients who were naive to IOP therapy (10 patients), the efficacy of AZOPT was similar to that seen previously in adults, with mean IOP reductions from baseline ranging up to 5 mmHg.
Blandt de patienter, som i forvejen fik topikal IOP- sænkende medicin (22 patienter), steg den gennemsnitlige IOP en smule i forhold til baseline i AZOPT gruppen.
Among patients who were on topical IOP-lowering medicinal products (22 patients), mean IOP increased slightly from baseline in the AZOPT group.
24 uger).
Due to its high affinity for CA-II, brinzolamide distributes extensively into the RBCs and exhibits a long halflife in whole blood (mean of approximately 24 weeks).
I den menneskelige organisme dannes metabolitten N- desethyl- brinzolamid som ligeledes bindes til kulsyre- anhydrasen (CA) og akkumuleres i deRBC.
In humans, the metabolite N-desethylbrinzolamide is formed, which also binds to CA and accumulates in RBCs.
Under tilstedeværelse af brinzolamid bindes denne metabolit hovedsagelig til CA- I.
This metabolite binds mainly to CA-I in the presence of brinzolamide.
I plasma er både brinzolamid og N- desethyl- brinzolamid koncentrationerne lave og ofte under grænseniveauet for bestemmelse for mængden (< 7, 5 ng/ ml).
In plasma, both brinzolamide and N-desethylbrinzolamide concentrations are low and generally below assay quantitation limits (< 7.5 ng/ ml).
60%).
Binding to plasma proteins is not extensive (about 60%).
60%).
Brinzolamide is eliminated primarily by renal excretion (approximately 60%).
20% af dosis genfindes i urinen som metaboliter.
About 20% of the dose has been accounted for in urine as metabolite.
Brinzolamid og N- Desethyl- brinzolamid er den prædominante komponent fundet i urinen sammen med mindre koncentrationer af N- desmethoxypropyl og O- desmethyl metabolitter.
Brinzolamide and N-desethyl-brinzolamide are the predominant components in the urine along with trace levels of the N-desmethoxypropyl and O-desmethyl metabolites.
I et peroralt farmakokinetisk studie, fik raske frivillige 1- mg kapsler med brinzolamid 2 gange dagligt i op til 32 uger, og de RBCs kulsyre- anhydrase (CA) aktivitet blev målt til at opnå samme niveau som systemisk CA- hæmning.
In an oral pharmacokinetic study, healthy volunteers received 1 mg capsules of brinzolamide twice daily for up to 32 weeks and RBC CA activity was measured to assess the degree of systemic CA inhibition.
20 μM).
Brinzolamide saturation of RBC CA-II was achieved within 4 weeks (RBC concentrations of approximately 20 µM).
N- desethyl- brinzolamid akkumuleredes i RBC til steady state i løbet af 20- 28 uger med koncentrationer fra 6- 30 μM.
N-Desethyl-brinzolamide accumulated in RBCs to steady state within 20-28 weeks reaching concentrations ranging from 6-30 µM.
70- 75%.
The inhibition of total RBC CA activity at steady state was approximately 70-75%.
Individer med moderat nedsat nyre funktion (Creatinin clearance på 30- 60 ml/ minut) modtog 1- mg brinzolamid 2 gange dagligt peroralt i op til 54 uger.
Subjects with moderate renal impairment (creatinine clearance of 30-60 ml/ minute) were administered 1 mg of brinzolamide twice daily orally for up to 54 weeks.
Brinzolamid RBC- koncentrationen var fra omkring 20 til 40 μM efter 4 ugers behandling.
Brinzolamide RBC concentration ranged from about 20 to 40 µM by week 4 of treatment.
Ved steady- state var brinzolamid og dens metabolit, i koncentrationer på henholdsvis fra 22, 0 til 46, 1 og 17, 1 til 88. 6 μM, respektivt.
At steady-state, brinzolamide and its metabolite RBC concentrations ranged from 22.0 to 46.1 and 17.1 to 88.6 µM, respectively.
N- desethyl- brinzolamid RBC- koncentrationerne voksede, og total RBC CA aktivitet aftog med faldende cratinin clearance, mens brinzolamid RBC koncentrationerne og CA- II forblev uforandrede.
N-desethyl-brinzolamide RBC concentrations increased and total RBC CA activity decreased with decreasing creatinine clearance but brinzolamide RBC concentrations and CA-II activity remained unchanged.
Ved patienter med den højeste grad af nedsat nyrefunktion var hæmningen af total CA aktivitet større, selvom den var mindre end 90% ved steady state.
In subjects with the highest degree of renal impairment inhibition of total CA activity was greater although it was inferior to 90% at steady-state.
I et topikalt okulært studie var steady- state for brinzolamid RBC koncentrationerne identisk med koncentrationerne fundet i det perorale studie, men niveauet for N- desethyl- brinzolamid var lavere.
In a topical ocular study, at steady-state, brinzolamide RBC concentrations were similar to those found in the oral study, but levels of N-desethyl-brinzolamide were lower.
40- 70% af niveauet før medicinering.
Carbonic anhydrase activity was approximately 40-70% of predose levels.
8 5. 3 Prækliniske sikkerhedsdata
8 5.3 Preclinical safety data
Tilførsel af brinzolamid i form af øjendråber til kaniner fra 1 til 6 måneder resulterede i en lille, statistisk signifikant øgning af cornea- tykkelsen, når det blev givet i koncentrationer på 1%, 2% og 4% fire gange dagligt; disse forandringer konstateredes ikke hos andre dyrearter.
Topical ocular administration of brinzolamide to rabbits for one to six months resulted in slight, statistically significant increases in corneal thickness when given at concentrations of 1%, 2% and 4%, four times a day; these changes were not observed in other species.